219 related articles for article (PubMed ID: 21343554)
1. Biology-driven phase II trials: what is the optimal model for molecular selection?
Andre F; Delaloge S; Soria JC
J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
[No Abstract] [Full Text] [Related]
2. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
3. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
4. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
5. A strategic framework for novel drug development in multiple myeloma.
Anderson KC; Hannah AL; Pazdur R; Farrell AT
Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
[No Abstract] [Full Text] [Related]
6. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
7. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
8. Emerging approaches to target tumor metabolism.
Ross SJ; Critchlow SE
Curr Opin Pharmacol; 2014 Aug; 17():22-9. PubMed ID: 25048629
[TBL] [Abstract][Full Text] [Related]
9. Epistatic interactions and drug response.
Weigelt B; Reis-Filho JS
J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
[TBL] [Abstract][Full Text] [Related]
10. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
11. SnapShot: glioblastoma multiforme.
Kotliarova S; Fine HA
Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
[No Abstract] [Full Text] [Related]
12. The role of targeted therapy in ovarian cancer.
Banerjee S; Kaye S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
[TBL] [Abstract][Full Text] [Related]
13. [Signal transduction and its targeting from the cancer molecular genetic platform: applications and perspectives in pulmonary pathology].
Merlio JP
Ann Pathol; 2011 Nov; 31(5 Suppl):S40-2. PubMed ID: 22054456
[No Abstract] [Full Text] [Related]
14. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
15. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
[No Abstract] [Full Text] [Related]
16. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
17. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
18. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
19. Developing drugs that do not cause tumor regression.
Stadler W
Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
[No Abstract] [Full Text] [Related]
20. From darkness to light with biomarkers in early clinical trials of cancer drugs.
Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
